Model DetailsLiver hepatocellular adenoma
Model Name |
Liver hepatocellular adenoma | Strain |
CD-1 |
Tumor Inducing Agent(s) |
None (spontaneous) |
Tumor Synonyms |
epithelial liver tumor • liver, hepatocellular adenoma • liver tumor • hepatocellular adenoma • liver adenoma • liver neoplasm • liver, adenoma, hepatocellular |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Liver | Male |
2.0% (1 of 49 mice) |
57 weeks |
|
Takahashi O, Toxicology 1997 Dec 26;124(2):95-103 |
| Liver | Male |
0% (0 of 3 mice) |
<57 weeks |
|
Takahashi O, Toxicology 1997 Dec 26;124(2):95-103 |
| Liver | Female |
0% (0 of 50 mice) |
57 weeks |
|
Takahashi O, Toxicology 1997 Dec 26;124(2):95-103 |
| Liver | Female |
0% (0 of 1 mice) |
<57 weeks |
|
Takahashi O, Toxicology 1997 Dec 26;124(2):95-103 |
| Liver | Male |
26% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
19.5% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Female |
1.0% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Female |
0.8% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
20.7% (12 of 58 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
13.3% (8 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
18.3% (11 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
15.7% (8 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
11.9% (7 of 59 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
28.3% (17 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
11.7% (7 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Male |
3.9% (2 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Female |
0% (0 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Female |
5.0% (3 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Liver | Female |
0% (0 of 33 mice) |
90 weeks |
|
Waalkes MP, Cancer Res 2006 Feb 1;66(3):1337-45 |
| Liver | Male |
11.0% (80 of 725 mice) |
|
Chandra M, Toxicol Lett 1992 Jun;61(1):67-74 | |
| Liver | Female |
1.8% (13 of 725 mice) |
|
Chandra M, Toxicol Lett 1992 Jun;61(1):67-74 | |
| Liver | Male |
26.4% (235 of 891 mice) |
up to 109 weeks |
|
Maita K, Toxicol Pathol 1988;16(3):340-9 |
| Liver | Female |
5.2% (46 of 890 mice) |
up to 109 weeks |
|
Maita K, Toxicol Pathol 1988;16(3):340-9 |
| Liver | Male |
8.3% (5 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Liver | Male |
5.0% (3 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Liver | Female |
0% (0 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Liver | Female |
1.7% (1 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Liver | Male |
observed |
≥1 year |
|
Brayton CF, Vet Pathol 2012 Jan;49(1):85-105 |
| Liver | Male |
0% (0 of 1453 mice) |
up to 39 weeks |
|
Son WC, Toxicol Lett 2003 Nov 1;145(1):88-98 |
| Liver | Male |
0.07% (1 of 1453 mice) |
up to 40 weeks |
|
Son WC, Toxicol Lett 2003 Nov 1;145(1):88-98 |
| Liver | Male |
0.07% (1 of 1453 mice) |
up to 50 weeks |
|
Son WC, Toxicol Lett 2003 Nov 1;145(1):88-98 |